Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer

Cells(2020)10.3390/cells9071643Source: DataRank Database

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer is a research paper published in Cells (2020). On theSindex it has a DataRank of 0. It has been cited 134 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access134 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 6.16)OA: goldTopics (48)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Hideo Takahashi ORCID,Yoshihisa Tokumaru ORCID,Li Yan ORCID,Omar M. Rashid ORCID,Masayuki Nagahashi ORCID

Live enrichment

PubMed:32650578 OpenAlex:https://openalex.org/W3042080296

National Institutes of Health

Grant: R01CA160688

Susan G. Komen

Grant: CCR17481211

National Cancer Institute

Grant: P30-CA016056

National Institutes of Health

Grant: 5R01CA160688-03

Sphingosine-1-phosphate in breast cancer progression and lymphangiogenesis

National Institutes of Health

Grant: 5P30CA016056-40

Roswell Park Cancer Institute Cancer Center Support Grant

FWCI

6.16

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2073-4409/9/7/1643/pdf?version=1594820363

publisherhttps://www.mdpi.com/2073-4409/9/7/1643/pdf?version=1594820363

publisherhttps://www.mdpi.com/2073-4409/9/7/1643/pdf

journalhttps://doi.org/10.3390/cells9071643

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32650578

Fields of Study

Cancer-related Molecular PathwaysAdvanced Breast Cancer TherapiesCancer Genomics and Diagnostics03 medical and health sciences0302 clinical medicine

MeSH Terms

Breast NeoplasmsFemaleHumansReceptors, EstrogenBiomarkers, TumorDisease-Free SurvivalReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesCell Cycle ProteinsE2F Transcription Factors

Keywords

Breast cancerE2FEstrogen receptorMedicineOncologyCancer researchNeoadjuvant therapyInternal medicineBiomarkerCyclin-dependent kinaseCancerImmune checkpointCell cycleBiologyImmunotherapysignaling pathwayBreast NeoplasmsCell Cycle ProteinsErb-b2 Receptor Tyrosine KinasesArticleDisease-Free SurvivalGSVAgene setBiomarkers, TumormetastasisHumansQH573-671treatment responsehormone receptorE2F Transcription FactorsReceptors, EstrogenFemaleCytology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759264.v1figshare

Additional file 1 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759264figshare

Additional file 2 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759267.v1figshare

Additional file 2 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759267figshare

Additional file 4 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759273figshare

Additional file 4 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759273.v1figshare

Additional file 6 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759279figshare

Additional file 5 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759276figshare

Additional file 3 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759270figshare

Additional file 7 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759282.v1figshare

Additional file 5 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759276.v1figshare

Additional file 7 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759282figshare

Additional file 3 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759270.v1figshare

Additional file 6 of Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer

10.6084/m9.figshare.26759279.v1figshare